Genzyme presents second Phase III study of once-daily oral AUBAGIO® (teriflunomide) confirming significant impact on disability Genzyme, 12 Oct 2012 Accessed on 16 Oct 2012 from http://www.businesswire.com/news/genzyme/20121012005423/en. CommentRecommendBookmarkWatch